A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum

Journal of Immunological Methods

Volumn 362, Issue 1-2, 2010, Pages 101-111

  Qiu, Zhihua Julia ^a   Ying, Yong ^a   Fox, Michael ^b   Peng, Kun ^a   Lewin Koh, Sock Cheng ^a   Coleman, Daniel ^a   Good, Jeremy ^a   Lowe, John ^a   Rahman, Amena ^a   Yang, Jihong ^a   Jiang, Jenny ^a   Quarmby, Valerie ^a   Song, An ^a  

^a GENENTECH INC   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Anti therapeutic antibody; Biotin digoxigenin bridging ELISA; Chicken anti DIG antibody; Electrochemiluminescence; Immunogenicity; Rheumatoid factors

Indexed keywords

AUTOANTIBODY; AVIDIN; BIOTIN; DIGOXIGENIN; DIGOXIN; HORSERADISH PEROXIDASE; HYDROCORTISONE; IMMUNOGLOBULIN G1 ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOTIN; CHEMILUMINESCENT MEASUREMENTS; CLINICAL TRIALS AS TOPIC; DIGOXIGENIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; SENSITIVITY AND SPECIFICITY;

ARMORACIA RUSTICANA;

EID: 77958509120     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.09.013     Document Type: Article

References (20)

1. Aybay C., Ozel S., Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol. Int. 2006, 26:473.
2. Bautista A., Yue E., Chirmule N., Swanson S., Jawa V. Elimination of rheumatoid factor interference in immunoassays using the electrochemiluminescence (ECL) based Meso Scale Discovery (MSD) platform. FASEB J. 2008, 22:lb566. Abstract.
3. Bubb M., Green F., Conradie J., Tchernyshev B., Bayer E.A., Wilchek M. Natural antibodies to avidin in human serum. Immunol. Lett. 1993, 35:277.
4. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J. Med. 2002, 346:469.
5. Cauffield S., Gums G., Grauer K. The serum digoxin concentration: ten questions to ask. Am. Fam. Physician 1997, 56:495.
6. Djukanovic R., Wilson S., Kraft M., Jarjour N., Steel M., Chung K., Bao W., Fowler-Taylor A., Matthews J., Busse W., Holgate S., Fahy J. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004, 170:583.
7. Hamilton Robert G. Rheumatoid factor interference in immunological methods. Monogr. Allergy 1989, 26:27.
8. Hoesel W., Gross J., Moller R., Kanne B., Wessner A., Müller G., Müller A., Gromnica-Ihle E., Fromme M., Bischoff S., Haselbeck A. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J. Immunol. Methods 2004, 294:101.
9. Koren E., Smith H., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S., Taniguchi G., Zuckerman L., Stebbins C., Mire-Sluis A. Recommendations on the risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1.
10. Kuter D., Begley C. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002, 100:3457.
11. Larsson A., Karlsson-Parra A., Sjöquist J. Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors. Clin. Chem. 1991, 37:411.
12. Larsson A., Bålöw R., Lindahl T., Forsberg P. Chicken antibodies: taking advantage of evolution-a review. Poult. Sci. 1993, 72:1807.
13. Mire-Sluis A., Barrett Y., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S., Taniguchi G., Wierda D., Zuckerman L. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1.
14. Mock D., Mock N. Serum concentrations of bisnorbiotin and biotin sulfoxide increase during both acute and chronic biotin supplementation. J. Lab. Clin. Med. 1997, 129:384.
15. Ng C., Bruno R., Combs D., Davies B. Population pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in rheumatoid arthritis patients during a Phase II clinical trial. J. Clin. Pharmacol. 2005, 45:792.
16. Pendley C., Schantz A., Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 2003, 5:172.
17. Vogel C., Cobleigh M., Tripathy D., Gutheil J., Harris L., Fehrenbacher L., Slamon D., Murphy M., Novotny W., Burchmore M., Shak S., Stewart S., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719.
18. Weber T., Käpyaho K., Tanner P. Endogenous interference in immunoassays in clinical chemistry. Scand. J. Clin. Lab. Invest. Suppl. 1990, 201:77.
19. Weisbart R., Noritake D., Colburn K., Saxton R. Human monoclonal IgG rheumatoid factor has structural homology with bacterial Fc receptor proteins. J. Immunol. 1987, 139:2925.
20. Xiao Y., Gao X., Gannot G., Emmert-Buck M., Srivastava S., Wagner P., Amos M., Barker P. Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int. J. Cancer 2008, 122:78.